Industry observers argue that medical technology companies can tap into increased healthcare spending among emerging economies while the U.S. market has matured and could experience slower growth. Looking ahead, in the years through 2024, spending growth is projected to average 5.8% and peak at 6.3% in 2020. CURE’s index allocates about a quarter of its weight to medical device, life sciences and healthcare technology companies.
The week starting Oct. 15 through the week ending Nov. 2 will be a critical period for CURE. Over that span, approximately 90% of the stock’s in CURE’s underlying index report third-quarter results, according to Direxion.
For more information on the markets, visit our current affairs category.